EXPERIENCE OF 1000 GASTRIC ADENOCARCINOMA CASES TREATED

Introduction: Stomach cancer is often asymptomatic in its early stages. Diagnosed by endoscopic examination. According to the National Cancer Institute (INCA) is the fourth most incident in Brazil and the third mortality in men and fifth in women. Objective: To analyze the outcomes and variables of more than 1,000 treated patients with gastric cancer. Method: This is a retrospective cohort study. Data were collected from the cancer registry and medical record analysis. Outcomes such as recurrent death and metastasis were analyzed and related to patient, tumor, and treatment variables. In addition to the descriptive analysis, survival was estimated by Kaplan Meier. Results: Between 2005 and 2014, 1076 cases of gastric cancer were treated. Of these, 1006 were adenocarcinoma (93.5%). A striking detail was that 71.3% had signet ring cells in histology. The median follow-up was 23 months. As for age, between 40 and 50 years had 38.9% of cases and 45.1% between 60 and 79 years, only 6.2% of patients were under 40 years. At the time of diagnosis, 41.4% of the patients were N0 and 32.9% were M1. Liver (41.7%) was the main site of metastasis. The estimated 5-year overall survival (SG) was 20%. Surgical treatment was performed in 48.9% of cases. SG was 38.1% in operated patients and 2.4% in non-operated patients (p <0.001), the main reason being the initial staging in the groups. Surgical patients had 25.8% stage II and 48.5% stage III, however, nonsurgical 88.2% were stage IV. Conclusions: Gastric adenocarcinoma, besides being prevalent, has high mortality. Diagnosis in advanced staging is the main risk factor. Despite advances in adjuvant and chemotherapy, visceral metastasis is still the leading cause of death.

 

MissingLinkText

No conflict of interest has been declared by the author(s).

Publication History

Article published online:
23 October 2019